Previous Close | 23.87 |
Open | 23.68 |
Bid | 22.60 x 100 |
Ask | 22.83 x 100 |
Day's Range | 22.63 - 23.85 |
52 Week Range | 17.52 - 45.00 |
Volume | |
Avg. Volume | 401,953 |
Market Cap | 613.047M |
Beta (5Y Monthly) | 2.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.